TRT(SH:600085) Huachuang Securities·2025-09-15 06:12Investment Rating - The report maintains a "Recommendation" rating for Tongrentang (600085) with a target price of 42.3 CNY [2][10]. Core Views - The company achieved a revenue of 9.77 billion CNY in 1H25, reflecting a year-on-year increase of 0.1%. However, the net profit attributable to shareholders decreased by 7.4% to 950 million CNY, primarily due to the challenging consumer environment, increased marketing expenses, and ongoing reforms [2][9]. - The report highlights the resilience of the company amid deepening reforms and emphasizes the potential for operational improvements in the coming years [9][10]. Financial Performance Summary - Revenue and Profitability: - 1H25 total revenue was 9.77 billion CNY, with a slight increase of 0.1% year-on-year. The net profit attributable to shareholders was 950 million CNY, down 7.4% year-on-year [2][9]. - The second quarter of 2025 saw revenue of 4.49 billion CNY, a decrease of 0.1% year-on-year, and a net profit of 360 million CNY, down 18.4% year-on-year [2][9]. - Financial Projections: - The projected total revenue for 2025 is 18.61 billion CNY, with a growth rate of 0.1%. The net profit is expected to remain flat at 1.53 billion CNY [5][10]. - For 2026 and 2027, the revenue is projected to grow to 20.52 billion CNY and 22.62 billion CNY, respectively, with net profit expected to reach 1.75 billion CNY and 2.02 billion CNY [5][10]. - Valuation Metrics: - The report assigns a target price based on a historical valuation of 38 times the expected earnings for 2025, leading to a target price of 42.3 CNY [9][10]. Segment Performance Summary - Traditional Chinese Medicine Segment: - The revenue for the traditional Chinese medicine segment in 1H25 was 3.02 billion CNY, showing a year-on-year increase of 16.1%. The gross margin improved by 3.1 percentage points to 44.7% [9]. - Technology Group: - The technology segment reported revenue of 3.74 billion CNY in 1H25, down 7.7% year-on-year, with a net profit of 480 million CNY, a decrease of 16.9% [9]. - Commercial Group: - The commercial segment generated revenue of 5.69 billion CNY, up 1.1% year-on-year, but net profit fell by 21.6% due to high base effects and consumer pressure [9]. Cash Flow and Financial Health - The report indicates a significant improvement in operating cash flow, which reached 1.95 billion CNY in 1H25, compared to only 0.1 billion CNY in the same period last year [9]. - The company's total assets are projected to grow from 31.20 billion CNY in 2024 to 36.92 billion CNY by 2027, with a debt-to-equity ratio of 21.5% in 2024, increasing to 26.9% by 2027 [10].